Neurocrine (NBIX) Biosciences announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Promising Market Potential and Therapeutic Advancements Drive Buy Rating for Neurocrine’s Crenessity
- Buy Rating on Neurocrine Due to Stabilization Prospects and Competitive Landscape Opportunities
- Neurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY Launch
- Neurocrine’s Potential Upside: Buy Rating Amid Market Overreaction and Pipeline Prospects
- Neurocrine initiated with a Hold at Deutsche Bank